CLBS16 for Coronary Microvascular Dysfunction (CMD)
CLBS16 is an experimental regenerative medicine which is currently being studied in a newly initiated Phase 2b study (the “FREEDOM trial”) taking place in the U.S. for the treatment of CMD.
CLBS12 (HONEDRA® in Japan) for Critical Limb Ischemia (CLI)
HONEDRA® is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of CLI and Buerger’s Disease by improving blood flow in the affected limb. Our open-label, registration-eligible study is actively enrolling patients in Japan and has shown promising results to date. CLBS12 has been granted orphan drug status in the U.S.A by the Food and Drug Administration (FDA).
Our proprietary CD34+ cell therapy platform has generated a multi-product development pipeline with the potential to provide curative therapies to people in need.
We’re working on the development of cell therapies that could help many people in need and restore health.
We combine deep scientific experience with a passion for changing the lives of patients.
CD34+ Cell Therapy Significantly Reduces Adverse Cardiac Events, Health Care Expenditures, and Mortality in Patients with Refractory Angina
Testing for Coronary Microvascular Dysfunction
Autologous CD34+ Cell Therapy for Ischemic Tissue Repair
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
Join Our Team
Our mission is to discover, develop and deliver innovative therapeutics in areas of unmet medical need that improve patient lives. We can accomplish that goal through the collective efforts of talented individuals who work together to advance scientific research. We place a premium on integrity, respect, diversity and collaboration. These values have helped us to build a growing company that offers professionally rewarding careers with the opportunity to make a meaningful contribution to patients in need.